RxDoctor Payments Data

Keri Merschman

Family Medicine · Tuscaloosa, ALNPI 1891107546

Payments from drug & device makers

$939in general payments, 2019–2025

Across 56 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$201
  • Amgen$178
  • Merck$85
  • AbbVie$73
  • GSK$55
  • Lilly USA, LLC$44
  • plus $303 from 13 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$939 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$2,085
Medicare patients
14
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin121$128,951
TrulicityDulaglutide116$126,228
MounjaroTirzepatide101$111,710
EliquisApixaban142$102,585
OzempicSemaglutide68$82,249
FarxigaDapagliflozin Propanediol75$49,450
Repatha SureclickEvolocumab49$30,632
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,906
JanuviaSitagliptin Phosphate43$18,268
XareltoRivaroxaban16$17,729
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$14,519
LinzessLinaclotide13$13,909
Victoza 3-PakLiraglutide13$10,419
Tresiba Flextouch U-100Insulin Degludec41$10,158
Bevespi AerosphereGlycopyrrolate/Formoterol Fum19$8,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$44$237,939217 claims
Boehringer IngelheimJardiance$25$128,951121 claims
PfizerEliquis$42$102,585142 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort$201$60,017105 claims
GSKTrelegy Ellipta, Anoro Ellipta$55$34,42541 claims
MerckJanuvia$85$18,26843 claims
Johnson & JohnsonXarelto$12$17,72916 claims
AbbVieLinzess$73$13,90913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →